Brachytherapy

Ann Pittier, MD, is recognized by Continental Who's Who

Retrieved on: 
Saturday, February 5, 2022
Trinity College, Radiation therapy, Uterine cancer, American Board of Radiology, Head, American Medical Association, Radiation, Multimedia, Cervical cancer, Prostate cancer, Medicine, Recurrence, Palliative care, Cancer, Breast, American Board of Internal Medicine, Exercise, Physics, Brachytherapy, Patient, University of Washington School of Medicine, University, Stress, Indian Medical Association, American Board of Commissioners for Foreign Missions, Continental, CME, Family, Concurrent estate, Risk, Breast cancer, Lung, Occidental College, Physician, Movement disorders, Metastasis, Vegetarianism, Society, ABIM, MD, Certification, Gig Harbor, Washington, Internal medicine, Medical imaging, Biology

As a young woman, Dr. Pittier was inspired to pursue a career in medicine and ultimately radiation oncology due to having multiple family members battle cancer.

Key Points: 
  • As a young woman, Dr. Pittier was inspired to pursue a career in medicine and ultimately radiation oncology due to having multiple family members battle cancer.
  • Because of this, she took on a unique perspective on fighting for cures and embracing palliative care when needed.
  • She notes that cancer does not simply affect the individual, but it touches everyone in the patient's life.
  • She works with each patient to help them gain personal control of risk factors to prevent recurrence or development of new cancers.

Sensus Healthcare to Host Fourth Quarter 2021 Financial Results and Business Update Conference Call on February 10, 2022

Retrieved on: 
Wednesday, January 26, 2022
ART, Nasdaq, Investor relations, Research, SensUs, Playback, Time, Keloid, Patient, Brachytherapy, International, SRT, Quality of life, GLOBE, BOCA, Medical imaging

In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Key Points: 
  • In addition, management will provide a business update and a discussion on recent and upcoming milestones.
  • To access the conference call, the dial-in numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-0702 (International).
  • Please direct the operator to be connected to the Sensus Healthcare conference call.
  • Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.

TeamBest Global Companies Announce Merger of Best ABT Molecular Imaging & Best Cyclotron Systems

Retrieved on: 
Friday, January 7, 2022
General Health, Health, Other Manufacturing, Manufacturing, Proton, Carbon, Cyclotron, Radiation therapy, Marvell Software Solutions Israel, Molecular imaging, Marketing, News, TBG, Solution, Dijon, Phosphorus, Medical imaging, Online shopping, Brachytherapy

Two of the TeamBest Global Companies, Best ABT Molecular Imaging and Best Cyclotron Systems, have merged into one entity effective January 1, 2022 Best Cyclotron Systems, Inc.

Key Points: 
  • Two of the TeamBest Global Companies, Best ABT Molecular Imaging and Best Cyclotron Systems, have merged into one entity effective January 1, 2022 Best Cyclotron Systems, Inc.
    Its global headquarters are located in Springfield, Virginia, with manufacturing operations in Knoxville (TN) and Loves Park (IL) USA, Ottawa (ON) and Vancouver (BC) Canada, as well as Dijon, France.
  • Best Cyclotron Systems, Inc. manufactures a broad range of cyclotron systems with a worldwide team to provide sales, service, marketing, and customer support.
  • The newly merged entity has over 35 cyclotrons installed worldwide from 6 MeV High Current Proton to 70 MeV High Current Proton Cyclotrons.
  • Currently, there are 10 plus cyclotrons of various energies under manufacturing, including a 70 MeV High Current Proton Cyclotron.

Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference

Retrieved on: 
Thursday, January 6, 2022
ART, Brachytherapy, Research, Patient, Keloid, Quality of life, Conference, BOCA, GLOBE, SRT, Nasdaq, Interest, Medical imaging, SensUs

BOCA RATON, Fla. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Joe Sardano, chairman and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Key Points: 
  • BOCA RATON, Fla. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Joe Sardano, chairman and chief executive officer, will present at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.
  • A pre-recorded presentation will be available on demand beginning Monday, January 10 at 7:00 a.m. Eastern time.
  • Also, Sensus management is holding virtual 1x1 meetings with members of the investment community concurrent with the 40th Annual J.P. Morgan Healthcare Conference January 10-14, 2022.
  • Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions.

Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Wednesday, January 5, 2022
ART, Brachytherapy, COVID-19, Dermatology, Government, Hyaluronic acid, Research, Forward-looking statement, Patient, CME, Axilla, Keloid, Quality of life, Conference, U.S. Securities and Exchange Commission, Annual report, Security (finance), Risk, Lidocaine, Awareness, CEO, Marketing, FDA, BOCA, Legislation, Diagnosis, Terminology, GLOBE, Center, SRT, Nasdaq, EBITDA, Industry, Cosmetic, Collagen, Perspiration, Tax, Pharmaceutical industry, Medical device, SensUs

Based upon expectations for shipments during the current quarter, the company also expects to be profitable for the first quarter of 2022.

Key Points: 
  • Based upon expectations for shipments during the current quarter, the company also expects to be profitable for the first quarter of 2022.
  • Sensus expects to report 2021 financial results and hold an investment community conference call in February.
  • Sensus also announces that its TransDermal Infusion System non-invasive drug delivery system for cosmetic and other dermatology applications will be featured at the 2022 Winter Clinical Dermatology Conference - Hawaii.
  • Mr. Sardano added, We are excited that our TransDermal Infusion System will be highlighted by Dr. Nestor at the Winter Dermatology Clinical.

RayStation 11B brings new features for adaptive workflows, brachytherapy, and radiation therapy with ions

Retrieved on: 
Thursday, December 16, 2021
Proton, Electron, RaySearch Laboratories, Radiation, Algorithm, Nasdaq Stockholm, TPS, Ion, Karolinska Institute, Cancer, Helium, CBCT, Photon, CEO, TCS, Neoplasm, OIS, Machine learning, Patient, CT, CTS, Brachytherapy, Linear energy transfer, Anatomy, OAS, Cell death, HDR, LET, Carbon, Medical imaging

A major feature of RayStation 11B is improved dose calculation accuracy on daily images for photon therapy.

Key Points: 
  • A major feature of RayStation 11B is improved dose calculation accuracy on daily images for photon therapy.
  • This provides an increased dose computation accuracy, which is crucial for establishing a more reliable adaptive workflow in radiation therapy.
  • Another vital feature of RayStation 11B is the possibility to convert a physical dose to the biological equivalent dose EQD2.
  • The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy.

Astera Cancer Care Expands into Northern and Southern New Jersey By Adding Three Practices to the OneOncology Platform

Retrieved on: 
Monday, December 6, 2021
Patient, CEO, Garden State, Prostate cancer, Brachytherapy, Lung cancer, Head, Cancer, Radiation, Clinical trial, Multiple myeloma, Doctor of Philosophy, Diversified Pharmaceutical Services, Proton therapy, Therapy, Breast cancer, B-cell lymphoma, Physician, Research, Health, Radiosurgery, Board, Academic health science centre, Board of directors, Oncology, Immunotherapy, LinkedIn, Multimedia, Colon, Medicine, Medical imaging

These acquisitions have expanded Astera's ability to deliver high-quality, coordinated and patient-centered cancer care throughout New Jersey.

Key Points: 
  • These acquisitions have expanded Astera's ability to deliver high-quality, coordinated and patient-centered cancer care throughout New Jersey.
  • "By bringing these exceptional practices into Astera Cancer Care, we are able to deliver to patients the highest-quality cancer care, including a portfolio of cutting-edge clinical trials, close to their homes no matter where they live in New Jersey," said Edward J. Licitra, MD, PhD, Chairman and CEO, Astera Cancer Care and a member of OneOncology's Board of Managers.
  • "From advanced diagnostics and therapies to a robust clinical trials program to one of the nation's leading value-based care programs, Astera Cancer Care is driving the future of cancer care in New Jersey," said Jeff Patton, MD, CEO, OneOncology.
  • Astera Cancer Care inspires hope and improves outcomes through its commitment to personalized patient care and the latest treatment and research.

Vivos Inc Obtains Feedback from the FDA on Clinical Testing of RadioGel™

Retrieved on: 
Thursday, December 2, 2021
Tissue, Private Securities Litigation Reform Act, Mayo Clinic, IDE, Sale, Washington, Half-life, Safety, Missouri, Technology, Hydrogel, Temperature, Forward-looking statement, Company, Neoplasm, Confusion, Sarcoma, Investigator's brochure, Brachytherapy, Human, University, Thyroid cancer, Review, Animal, Physician, Vivos, GLOBE, Marketing, OTCQB, Food and Drug Administration, Investigational device exemption, FDA, Radiation, Gel, Washington State University Reactor, Name, Engineering, Veterinary medicine, FDA Center for Devices and Radiological Health, Skin cancer, Method, Structured Product Labeling, Food, Mayo, Medical device, Pharmaceutical industry, Medical imaging

The FDA provided many helpful suggestions on a range of subjects from labeling to dosimetry to the Mayo protocol for clinical testing, and the need for some additional specific testing.

Key Points: 
  • The FDA provided many helpful suggestions on a range of subjects from labeling to dosimetry to the Mayo protocol for clinical testing, and the need for some additional specific testing.
  • This was the first time the Mayo Clinic Doctors met with the FDA regarding RadioGel.
  • They were able to communicate the unmet medical need that RadioGel could address and successfully fielded several key questions from the FDA reviewers.
  • Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel).

Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System

Retrieved on: 
Wednesday, December 1, 2021
Patient, SRT, Skin, Government, Security (finance), CEO, Risk, Permeability, Technology, Axilla, Brachytherapy, Industry, Annual report, Forward-looking statement, Cosmetic, Collagen, Dermatology, ART, Engineering, Injection, Toxin (comics), Iontophoresis, U.S. Securities and Exchange Commission, Hyaluronic acid, COVID-19, Pain, Perspiration, Legislation, Quality of life, Center, Nasdaq, Research, Tax, GLOBE, Marketing, Keloid, Terminology, System, FDA, BOCA, General surgery, Lidocaine, Skin care, Food, Medical device, Medical imaging

Italia S.P.A. for its TransDermal Infusion System non-invasive drug delivery system.

Key Points: 
  • Italia S.P.A. for its TransDermal Infusion System non-invasive drug delivery system.
  • Sensus sales organization will market the system to dermatologists for skin rejuvenation treatments, pre-laser treatments, pre- and post-plastic surgery and other applications.
  • In addition, Sensus plans to make rental programs and leasing facilities available, similar to current programs for its superficial radiation therapy and aesthetic lasers.
  • Their device, which we intend to trademark as TransDermal Infusion under the Sensus brand, is FDA-cleared for use on any part of the body currently treated with needle injections.

More cancer patients in Africa to benefit from advanced radiation therapy with Elekta Unity MR-Linac

Retrieved on: 
Thursday, November 25, 2021
ACCESS, Man, Unity, Brachytherapy, Management of prostate cancer, Hospital, Neoplasm, Woman, Anatomy, Cancer, Health, Edinburgh Cancer Research Centre, EKTA, Winnipeg International Children's Festival, Calendar, APAC, Medical imaging

STOCKHOLM, Nov. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less than six months after the company introduced its ACCESS 2025 strategy, which includes giving more than 300 million people access to radiation therapy with the addition of 800 to 1,000 additional Elekta linacs in underserved markets.

Key Points: 
  • As a member of the Elekta MR-Linac Consortium, ICCRC will actively investigate the potential benefits of magnetic resonance-guided radiation therapy (MRgRT) in pediatric oncology.
  • In addition, ICCRC will join hospitals around the world in providing high precision radiation therapy to treat cancer in children.
  • And Elekta Unity uses dynamic real-time adaptation to tailor treatment based on changes in the shape, size and position of the tumor and surrounding anatomy.
  • * Elekta Studio is comprised of multiple medical devices, some of which may not yet be available in all markets.